BioCentury | Feb 26, 2020
Product Development

U.S. testing of coronavirus vaccine, therapeutic begin

NIH is kicking off the first U.S. clinical trials for COVID-19 with an adaptive trial of remdesivir, an antiviral therapeutic, and a Phase I trial of Moderna’s vaccine candidate. Separately Tuesday, FDA Commissioner Stephen Hahn...
BioCentury | Feb 24, 2020

Biopharma stocks tumble as drug supply chain risk mounts

Biotech indexes lost considerable ground during Monday’s trading session amid concerns of global supply chain disruptions due to the COVID-19 outbreak, although biotechs were generally spared the worst of the day’s losses, dipping by a...
BioCentury | Feb 8, 2020
Product Development

Feb. 7 Product Development Quick Takes: Myriad tumbles on revenue miss; plus Verana, Sanofi, VIB, Coda, Blueprint

Myriad misses Street as CEO Capone departs Myriad Genetics Inc. (NASDAQ:MYGN) fell $8.27 (28%) to $21.02 after reporting fiscal 2Q20 EPS and revenues that missed consensus estimates and announcing the departure of President and CEO...
BioCentury | Feb 6, 2020

Beyond Keytruda: How Merck envisions innovation and growth after a spinout

As Merck becomes the latest large pharma to split in two, separating its key growth drivers and innovative programs from its slower-growing businesses, the slimmed-down innovative company will rely on the fruits of recent and...
BioCentury | Jan 4, 2020

Politics aside, 2020 could be a good year for bringing back generalists

After largely being out of biotech stocks for four years, generalist investors have shown signs that they are ready to dip their toes again in 2020. The fourth quarter surge, and a spate of 2019...
BioCentury | Jan 1, 2020

Fewer FDA approvals in 2019, but a basket of firsts

While the year held fewer approvals of new molecular entities than 2018, it was not short of major achievements. FDA greenlit several drugs with innovative modalities, against novel targets and for diseases that have long...
BC Extra | Jan 1, 2020
Financial News

Fourth quarter rally pushes biotech to strong finish

Biotech indexes rose as much as 33% in 2019 despite gaining little value overall in the year’s first nine months, with a series of clinical catalysts and strong appetite for M&A and licensing deals fueling...
BC Extra | Dec 17, 2019
Clinical News

BeiGene looks beyond Phase III setback to build case for Brukinsa

Although a Phase III miss in Waldenström’s macroglobulinemia scuttles Brukinsa’s near-term chances to add a superiority claim to its label, BeiGene believes the Btk inhibitor's combined efficacy and safety profile differentiates it from Imbruvica. BeiGene...
BC Extra | Dec 13, 2019
Preclinical News

Dec. 12 Preclinical Quick Takes: POC for Aptose blood cancer candidate, plus Penn-Acorn AI, Neurimmune-Biogen and Syndax

Efficacy for Btk, FLT3 inhibitor in blood cancers  In a pair of posters at the American Society of Hematology (ASH) meeting in Orlando, Aptose Biosciences Inc. (NASDAQ:APTO; TSX:APS) and University of Texas MD Anderson Cancer...
BC Innovations | Dec 11, 2019
Product Development

The writing has been on the wall for Sanofi’s diabetes, CV business for years

One hundred days after taking the helm as CEO, Paul Hudson has outlined a plan to get Sanofi to 30% margins by 2022 that hinges largely on the success of Dupixent and five other priority...
Items per page:
1 - 10 of 608